Jason Silversteen, DO
Neurology · Newark, DENPI 1174783237
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $182,953 of the $202,195 with a category attached, or 90.5%. 16 manufacturers reported payments, led by EMD Serono, Inc. at 39.9% of the total. Reporting peaked in 2022 at $57,186 and has fallen 96.0% since, to $2,278 in 2025. Among neurology clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $1520.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$81K
- Biogen$51K
- Genentech USA, Inc.$50K
- Amgen$17K
- Genentech, Inc.$3K
- Sanofi$119
- plus $265 from 10 others
Across 48 payments — averaging $36,981 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.7M
- Sanofi$15K
- Biogen$12K
- AstraZeneca$3K
What the payments were for
- Consulting fees$13,7297%
- Speaking & faculty fees$182,95390%
- Food & beverage$5,4103%
- Education$1030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| EMD Serono, Inc. | 51 | $80,752 |
| Biogen | 31 | $51,288 |
| Genentech USA, Inc. | 25 | $49,502 |
| Amgen(2 entities) | 10 | $16,800 |
| Genentech, Inc. | 4 | $3,470 |
| Sanofi | 1 | $119 |
| TG Therapeutics, Inc. | 1 | $103 |
| Greenwich Biosciences, Inc. | 1 | $29 |
| CSL Behring | 1 | $23 |
| Akcea Therapeutics, Inc. | 2 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Novartis | 1 | $12 |
| Bristol Myers Squibb | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$202,195 in reported general payments places this provider in the 95th percentile of 61 neurology providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcrevusOcrelizumab | 65 | $2,495,137 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 180 | $1,033,551 |
| Kesimpta PenOfatumumab | 80 | $752,449 |
| SolirisEculizumab | 13 | $655,571 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 36 | $616,887 |
| RebifInterferon Beta-1a/Albumin | 32 | $435,756 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 33 | $434,379 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 28 | $328,759 |
| FingolimodFingolimod Hcl | 85 | $252,841 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $236,600 |
| TecfideraDimethyl Fumarate | 13 | $213,752 |
| Avonex (4 Pack)Interferon Beta-1a | 24 | $192,192 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 17 | $184,443 |
| CopaxoneGlatiramer Acetate | 18 | $163,691 |
| VumerityDiroximel Fumarate | 19 | $156,957 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Ocrevus | $3,470 | $2,495,13765 claims |
| CSL BehringPrivigen, Hizentra | $23 | $853,48862 claims |
| BiogenTecfidera, Avonex (4 Pack), Vumerity, Tysabri | $51,288 | $705,90076 claims |
| EMD Serono, Inc.Rebif | $80,752 | $435,75632 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $18 | $163,69118 claims |
| SanofiAubagio | $119 | $119,71613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 61 neurology providers in Delaware.
Other neurology in Newark
- Justin MartelloNewark$485K
- Etsegenet TizazuNewark$15K
- William SommersNewark$14K
- Lee DresserNewark$12K
- John PollardNewark$7K
- Shilpa KautaNewark$7K
- Brian OommenNewark$2K
- Huijun WangNewark$1K
- Muhammad AfzalNewark$1K
- Sandeep DevarapalliNewark$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.